Researchers developed a 220-sample pan-cancer patient-derived organoid platform that faithfully mirrors tumors and may ...
Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results